novocure Optune - What Are the Benefits of Treatment with Optune?

11
6 What Are the Benefits of Treatment with Optune
®
?
Patients using Optune after their tumor reappeared lived a similar amount of time compared to patients using
cancer drugs. In the clinical study, half of the patients in both groups lived for more than 6.4 months. 22 out of
each 100 patients lived for one year or longer.
Patients using Optune after their tumor reappeared had a better quality of life (see Section 7).
Below is a table showing the eects on the benefit of the device, when it is used correctly or incorrectly after
the tumor reappeared.
Benefit from Correct and Incorrect Use of Optune
Event Likelihood of Event Outcome Likelihood of Outcome
Correct use
Use of the device for at least
18 hours a day
85 out of 98 subjects (87%) Survival 3 months longer
compared to subjects treated
less than 18 hours a day
81 out of 85 (95%)
Incorrect use
Use of the device for less
than 18 hours a day
13 out of 98 subjects (13%) Survival 3 months shorter
compared to subjects treated
at least 18 hours a day
12 out of 13 (92%)
Wetting the device or soaking
the transducer arrays
Unknown Treatment break Unknown
Handling of the device by
children
Unknown Treatment break Unknown
In the clinical study using Optune with temozolomide before patients’ tumors reappeared, the time from the start of
treatment to death was measured when half of the patients had joined the study as well as at the time when all of the
total 700 patients had joined the study. The table below shows the amount of time that patients who used Optune with
temozolomide were observed to be alive longer than patients who used temozolomide alone.
Benefit of Optune + Temozolomide
Half of Patients in Study All Patients in Study
Correct use Almost 5 months longer Almost 7 months longer
All subjects 3 months longer Almost 5 months longer
In addition, more patients who used Optune with temozolomide were alive after 2 years than patients using
temozolomide alone:
Patients Alive 2 Years after the Start of Treatment
(Optune + Temozolomide vs. Temozolomide Alone)
Half of Patients in Study All Patients in Study
Correct use 48% vs. 32% 43% vs. 25%
All subjects 48% vs. 34% 43% vs. 31%
What Are the Benefits of Treatment with Optune?\\DC - 099263/000001 - 12620961 v1